Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HR+/HER2-breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT04408118
What this trial is testing

First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC

Who this might be right for
Metastatic Breast CancerAdvanced Breast CancerTriple Negative Breast Cancer
MedSIR 100
Not applicableStudy completedNCT05770713
What this trial is testing

A Real-life Study to Learn About the Use and Effects of the CDK4/6 Inhibitors in Canadian Patients With Breast Cancer.

Who this might be right for
Breast Cancer
Pfizer 48
Testing effectiveness (Phase 2)Active Not RecruitingNCT04215146
What this trial is testing

Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study

Who this might be right for
Breast Cancer Metastatic
Oncolytics Biotech 48
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07441486
What this trial is testing

A Single-arm, Prospective, Phase II Clinical Study of the Combination of Entinostat and Oral Paclitaxel in the Treatment of HR+HER2- Advanced Breast Cancer

Who this might be right for
Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 50
Post-approval studies (Phase 4)Not Yet RecruitingNCT06613373
What this trial is testing

An Exploratory Clinical Study of CDK4/6i Dalpiciclib Combined With AI Neoadjuvant Therapy for Stage II-III HR+/HER2- Breast Cancer

Who this might be right for
Breast Cancer
Jiangsu Famous Medical Technology Co., Ltd. 30
Testing effectiveness (Phase 2)UnknownNCT05205200
What this trial is testing

Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02

Who this might be right for
Breast CancerMetastatic Cancer
Fudan University 338
Early research (Phase 1)Study completedNCT01857193
What this trial is testing

Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 132
Testing effectiveness (Phase 2)UnknownNCT03638648
What this trial is testing

Recurrence Score-guiding Chemotherapy in Non-pCR HR Positive HER2 Negative Breast Cancer After Neoadjuvant Therapy

Who this might be right for
Breast Cancer
Zhejiang Cancer Hospital 80
Testing effectiveness (Phase 2)Looking for participantsNCT07498478
What this trial is testing

Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment

Who this might be right for
Breast Cancer
TransThera Sciences (Nanjing), Inc. 94
Not applicableStudy completedNCT05399329
What this trial is testing

Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan

Who this might be right for
Breast Cancer
Pfizer 693
Not applicableUnknownNCT04030728
What this trial is testing

Implementing Patients´ Competence in Oral Breast Cancer Therapy

Who this might be right for
Metastatic Breast CancerAdvanced Breast Cancer
Onco Medical Consult GmbH 212
Testing effectiveness (Phase 2)Study completedNCT03227328
What this trial is testing

CDK4/6-inhibitor or Chemotherapy, in Combination with ENDOcrine Therapy, for Advanced Breast Cancer / KENDO

Who this might be right for
Hormone Receptor Positive Breast CancerMetastatic Breast CancerHormone Receptor Negative Breast Cancer
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 52
Testing effectiveness (Phase 2)Looking for participantsNCT05728268
What this trial is testing

Neoadjuvant Dose-dense Chemotherapy for HR+/HER2- Breast Cancer Patients With High Proliferation Index

Who this might be right for
Breast Cancer
Shantou Central Hospital 64
Testing effectiveness (Phase 2)UnknownNCT06133088
What this trial is testing

Dalpiciclib Combination With Fulvestrant and Compound Gossyfol Acetate Tablets in Women With CDK4/6 Inhibitor-refractory HR-positive HER-2 Negtive Metastatic Breast Cancer: a Phase 2 Clinical Trial.

Who this might be right for
Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed
Zhejiang Cancer Hospital 53
Testing effectiveness (Phase 2)Looking for participantsNCT05985655
What this trial is testing

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

Who this might be right for
Head and Neck Squamous Cell Carcinoma (HNSCC)Pancreatic AdenocarcinomaNon-small Cell Lung Cancer (NSCLC)+3 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. 230
Testing effectiveness (Phase 2)Active Not RecruitingNCT05165225
What this trial is testing

Phase II Neoadjuvant Pyrotinib Combined With Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial

Who this might be right for
Breast CancerHER2-low-expressing Breast CancerHormone Receptor-positive Breast Cancer+1 more
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 48
Large-scale testing (Phase 3)Active Not RecruitingNCT04494425
What this trial is testing

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

Who this might be right for
Advanced or Metastatic Breast Cancer
AstraZeneca 866
Large-scale testing (Phase 3)Active Not RecruitingNCT05840211
What this trial is testing

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

Who this might be right for
Locally Advanced or Unresectable Metastatic Breast CancerStage IV Breast Cancer
Gilead Sciences 654
Not applicableStudy completedNCT04735367
What this trial is testing

Study to Evaluate Overall Survival in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Letrozole

Who this might be right for
Breast Cancer
Pfizer 42
Testing effectiveness (Phase 2)Looking for participantsNCT06439771
What this trial is testing

Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC

Who this might be right for
Locally Advanced or Metastatic Breast Cancer
MediLink Therapeutics (Suzhou) Co., Ltd. 180
Next Page